SOURCE: SkyePharma PLC

November 18, 2009 02:00 ET

Skyepharma PLC - Board Change

LONDON--(Marketwire - November 18, 2009) -


LONDON, UK, 18 November, 2009 - SkyePharma PLC (LSE: SKP) regrets to
announce today that its Chairman, Jeremy Scudamore, has informed the
Board that he intends to step down from the Board at the end of 2009
for health reasons.

Frank Condella, Non-Executive Director and former CEO of
SkyePharma, has agreed to take over as Non-Executive Chairman with
effect from 1 January 2010.

Dr Ken Cunningham, CEO of SkyePharma, commented: "The Board thanks
Jeremy for his valuable contribution as Chairman of the Company since
October 2007 and wishes him a speedy and successful recovery.  We are
very fortunate that Frank Condella is able to take over from Jeremy as
Chairman of SkyePharma. Frank will bring a strong sense of continuity
to the position as well as a deep understanding of the business and we
all look forward to continuing to work with him in his new role."

Editors' Note

Frank Condella was Chief Executive Officer of SkyePharma PLC from 1
March 2006 until 1 September 2008 and has been a Non-Executive Director
since 1 November 2008.  Aged 55, Frank Condella is a Non-Executive
Director of Fulcrum Pharma plc and an independent Director of Columbia
Laboratories, Inc. Previously, he was President of European Operations
at IVAX, Chief Executive officer of Faulding Pharmaceutical Co.,
Vice-President of the Specialty Care Products business at Roche and
Vice-President and General Manager of the Lederle unit of American Home

For further information please contact:

SkyePharma PLC

Ken Cunningham, Chief Executive Officer       +44 207 491 1777
Peter Grant, Chief Financial Officer

Financial Dynamics
Jonathan Birt/Susan Quigley                   +44 207 831 3113

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of known molecules to provide a clinical advantage and
life-cycle extension. The Group has twelve approved products in the
areas of oral, inhalation and topical delivery. The Group's products
are marketed throughout the world by leading pharmaceutical companies.
For more information, visit

                    This information is provided by RNS
          The company news service from the London Stock Exchange


Contact Information